K Y Smith

Summary

Affiliation: Rush University Medical Center
Country: USA

Publications

  1. ncbi Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
    K Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Infect Dis 181:141-7. 2000
  2. ncbi Initiating antiretroviral therapy in asymptomatic HIV patients
    Kimberly Y Smith
    Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:13S-16S. 2004
  3. ncbi Disparities and gaps in HIV research and care
    Kimberly Y Smith
    Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:5S-7S. 2004
  4. ncbi Optimizing care for African-American HIV-positive patients
    Kimberly Y Smith
    Rush Medical College and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    AIDS Patient Care STDS 17:527-38. 2003
  5. ncbi Protease inhibitor-sparing regimens
    Kimberly Y Smith
    Department of Medicine, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA
    J Int Assoc Physicians AIDS Care (Chic Ill) 1:116-20. 2002
  6. ncbi Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174
    Kimberly Smith
    Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS Res Hum Retroviruses 26:425-32. 2010
  7. ncbi Selected metabolic and morphologic complications associated with highly active antiretroviral therapy
    Kimberly Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Infect Dis 185:S123-7. 2002
  8. ncbi T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals
    C M Steffens
    Department of Immunology/Microbiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA
    AIDS 15:1757-64. 2001
  9. ncbi Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients
    L Al-Harthi
    Department of Immunology Microbiology, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    HIV Med 5:55-65. 2004
  10. ncbi Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Kimberly Y Smith
    Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS 23:1547-56. 2009

Research Grants

  1. Growth Hormone and Immune Reconstitution in HIV Disease
    Kimberly Smith; Fiscal Year: 2004

Collaborators

Detail Information

Publications20

  1. ncbi Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy
    K Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    J Infect Dis 181:141-7. 2000
    ..These findings suggest that there is a complex relationship among the thymus, viral replication, and lymphocyte restoration after application of HAART in HIV disease...
  2. ncbi Initiating antiretroviral therapy in asymptomatic HIV patients
    Kimberly Y Smith
    Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:13S-16S. 2004
  3. ncbi Disparities and gaps in HIV research and care
    Kimberly Y Smith
    Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60614, USA
    J Natl Med Assoc 96:5S-7S. 2004
  4. ncbi Optimizing care for African-American HIV-positive patients
    Kimberly Y Smith
    Rush Medical College and Rush Presbyterian St Luke s Medical Center, Chicago, Illinois, USA
    AIDS Patient Care STDS 17:527-38. 2003
    ....
  5. ncbi Protease inhibitor-sparing regimens
    Kimberly Y Smith
    Department of Medicine, Rush Medical College, Rush-Presbyterian-St. Luke's Medical Center, Chicago, USA
    J Int Assoc Physicians AIDS Care (Chic Ill) 1:116-20. 2002
  6. ncbi Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174
    Kimberly Smith
    Section of Infectious Diseases, Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS Res Hum Retroviruses 26:425-32. 2010
    ..Treatment with rhGH +ART may be associated with modest increases in CD4 lymphocytes over ART alone in subjects with CD4 <350, yet the origin of these naive cells and their impact on immune function require further investigation...
  7. ncbi Selected metabolic and morphologic complications associated with highly active antiretroviral therapy
    Kimberly Y Smith
    Section of Infectious Diseases, Rush Presbyterian St Luke s Medical Center, Chicago, Illinois 60612, USA
    J Infect Dis 185:S123-7. 2002
    ..Treatment regimens directed at these abnormalities are being developed, but clinical trials are needed to fully ascertain the efficacy and safety of such interventions...
  8. ncbi T cell receptor excision circle (TREC) content following maximum HIV suppression is equivalent in HIV-infected and HIV-uninfected individuals
    C M Steffens
    Department of Immunology/Microbiology, Rush-Presbyterian-St Luke's Medical Center, Chicago, Illinois 60612, USA
    AIDS 15:1757-64. 2001
    ....
  9. ncbi Evaluation of the impact of highly active antiretroviral therapy on immune recovery in antiretroviral naive patients
    L Al-Harthi
    Department of Immunology Microbiology, Rush Presbyterian St Luke s Medical Center, Chicago, IL 60612, USA
    HIV Med 5:55-65. 2004
    ..To examine the extent of immune reconstitution in treatment-naive patients with CD4 T-cell counts <500 cells/microL following 48 weeks of highly active antiretroviral therapy (HAART)...
  10. ncbi Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment
    Kimberly Y Smith
    Rush University Medical Center, Chicago, Illinois 60612, USA
    AIDS 23:1547-56. 2009
    ..This is the first completed, randomized clinical trial to directly compare the efficacy, safety, and tolerability of these agents, each in combination with lopinavir/ritonavir in antiretroviral-naive patients...
  11. ncbi HIV-1-infected antiretroviral-treated patients with prolonged partial viral suppression: clinical, virologic, and immunologic course
    Allan R Tenorio
    Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts, USA
    J Acquir Immune Defic Syndr 34:491-6. 2003
    ..HIV-specific CD4+ T-cell immunity was detected in most subjects with low-level and undetectable viremia and may have a role in controlling viremia in the setting of partial suppression...
  12. ncbi Classic pyomyositis of the extremities as an unusual manifestation of Blastomyces dermatitidis: a report of two cases
    Michael Y Lin
    Section of Infectious Diseases, Rush University Medical Center, Chicago, IL 60612, USA
    Mycoses 53:356-9. 2010
    ..dermatitidis, particularly of the extremity muscles, is unique. We conclude that B. dermatitidis is a potential cause of classic pyomyositis...
  13. ncbi A pilot study of the safety and efficacy of cholestin in treating HIV-related dyslipidemia
    Joyce K Keithley
    Rush University College of Nursing, Chicago, Illinois 60612, USA
    Nutrition 18:201-4. 2002
    ..We collected preliminary safety and efficacy data on the effects of Cholestin, a statin-containing dietary supplement, in individuals with dsylipidemia related to human immunodeficiency virus...
  14. ncbi Electron beam computed tomography for assessment of coronary artery disease in HIV-infected men receiving antiretroviral therapy
    Rohit Talwani
    Section of Infectious Diseases, Department of Medicine, Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA
    J Acquir Immune Defic Syndr 30:191-5. 2002
    ..These results need to be confirmed in larger long-term studies, with controls well matched for coronary risk factors...
  15. ncbi Recognizing and managing common toxicities in patients receiving antiretroviral therapy
    M Keith Rawlings
    Peabody Health Center, Dallas, Texas, USA
    AIDS Read 14:S12-5. 2004
    ..An understanding of the drug-specific, class-specific, and general toxicities and side effects of antiretroviral drugs will help the clinician tailor treatment regimens to individual patients...
  16. ncbi Role of Baseline pol Genotype in HIV-1 Fitness Evolution
    Jan Weber
    Department of Virology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    J Acquir Immune Defic Syndr 33:448-60. 2003
    ..65, P < 0.0001). However, our results suggest that the preexistence of secondary mutations in protease genetic background may have implications in HIV-1 fitness evolution and virologic response to antiretroviral therapy...
  17. ncbi Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease
    Hernan Valdez
    Case Western Reserve University, University Hospitals of Cleveland Center for AIDS Research, Ohio, USA
    AIDS 16:1859-66. 2002
    ..The clinical significance of incomplete reconstitution of CD4 lymphocyte number, phenotype, and proliferative function in HIV-1 infection remains to be determined...
  18. ncbi Immune reconstitution after successful treatment with protease inhibitor-based and protease inhibitor-sparing antiretroviral regimens
    Kimberly Y Smith
    J Acquir Immune Defic Syndr 29:544-5. 2002
  19. ncbi Improving adherence to HAART
    Valerie E Stone
    Massachusetts General Hospital, Boston, MA 02114, USA
    J Natl Med Assoc 96:27S-29S. 2004
  20. ncbi CCR5 and CXCR4 expression after highly active antiretroviral therapy (HAART)
    Kimberly Y Smith
    J Acquir Immune Defic Syndr 30:458-60. 2002

Research Grants1

  1. Growth Hormone and Immune Reconstitution in HIV Disease
    Kimberly Smith; Fiscal Year: 2004
    ..abstract_text> ..